Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05897541 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection
A Phase 3 study, sponsored by Shionogi.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,387
- Enrollment target
NCT05897541: Completed Phase 3 study, sponsored by Shionogi.
NCT05897541 is a Phase 3 study that has completed, run by Shionogi. The registered enrollment target is 2,387 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (209% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05897541, a Phase 3 study, has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,387 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the proportion of participants who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (positive reverse transcription polymerase chain reaction \[RT-PCR\] test) and have coronavirus disease 2019 (COVID-19) symptom(s) with S-217622 tablets compared with placebo tablets in participants who are household contacts of an individual with symptomatic COVID-19.
Interventions
- DRUG Placebo
- DRUG S-217622
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,387 participants |
| Start Date | 2023-06-09 |
| Est. Completion | 2024-09-18 |
| Phase | Phase 3 |
What the finished NCT05897541 record still lists
NCT05897541 is an interventional study that assigns participants to a tested intervention. Its 2,387 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (209% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05897541 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05897541 about?
NCT05897541 is a clinical study titled "Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection". The purpose of this study is to measure the proportion of participants who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (positive reverse transcription polymerase chain reaction \[RT-PCR\] test) and have coronavirus disease 2019 (COVID-19) symptom(s) with S-217622 t...
What is the current status of trial NCT05897541?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,387 participants. The study started on 2023-06-09. Estimated completion is 2024-09-18.
What interventions are being tested in trial NCT05897541?
The interventions under investigation include: Placebo (DRUG), S-217622 (DRUG).
Who is sponsoring clinical trial NCT05897541?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05897541's enrollment target sits among peer trials
2,387 91st of 2000 higher than 1,910 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06747494 · 2,396 participants · NA
General vs Spinal in Total Joint Arthroplasty (TJA)
- NCT05868421 · 2,376 participants · NA
Veteran Social Support for Enhancing Use of Smoking Cessation Treatment
- NCT05185440 · 2,400 participants · NA
Reducing Alcohol Involved Sexual Violence in Higher Education
- NCT05285527 · 2,400 participants · NA
MiSight 1 Day Safety Post-Approval Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI